Wellbeing Digital Sciences Inc. (MEDI.NE)
| Previous Close | 0.0150 |
| Open | 0.0150 |
| Bid | 0.0050 x N/A |
| Ask | 0.0150 x N/A |
| Day's Range | 0.0100 - 0.0150 |
| 52 Week Range | 0.0100 - 1.9000 |
| Volume | |
| Avg. Volume | 0 |
| Market Cap | 1.034M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.4010 |
| Earnings Date | Sept 15, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Business Wire
Wellbeing Provides Bi-Weekly Default Status Report
VANCOUVER, British Columbia, March 16, 2023--Wellbeing Digital Sciences Inc. ("Wellbeing" or the "Company") (NEO: MEDI) (OTC: KONEF) (FRA: SQ2) is providing this update with respect to the management cease trade order ("MCTO") issued by the British Columbia Securities Commission ("BCSC") on January 31, 2023, as previously announced by the Company on February 1, 2023 (the "Default Announcement"). The MCTO was issued in connection with the filing of the Company’s audited annual financial statement
- Business Wire
Wellbeing Digital to Participate at the Benzinga Psychedelic Capital Conference
VANCOUVER, British Columbia, March 16, 2023--Wellbeing Digital Sciences Inc. ("Wellbeing" or the "Company") (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, announces that Najla Guthrie, CEO, will participate at the upcoming Benzinga Psychedelic Capital Conference taking place on April 13th, 2023
- Business Wire
Wellbeing Digital to Participate at the Cantor Fitzgerald Virtual Panel Discussion
VANCOUVER, British Columbia, March 13, 2023--Wellbeing Digital Sciences Inc. ("Wellbeing" or the "Company") (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, announces that Najla Guthrie, CEO, will participate virtually at the upcoming Cantor Fitzgerald Psychedelic Clinics panel discussion on Marc
